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RECK is a novel tumour suppressor gene that negatively regulates matrix metalloproteinases (MMPs) and inhibits tumour invasion,
angiogenesis and metastasis. In the present study, we investigated the effects of epigallocatechin-3-gallate (EGCG), a major
polyphenol in green tea, on the methylation status of the RECK gene and cancer invasion in oral squamous cell carcinoma cell lines.
Our results showed that treatment of oral cancer cells with EGCG partially reversed the hypermethylation status of the RECK gene
and significantly enhanced the expression level of RECK mRNA. Inhibition of MMP-2 and MMP-9 levels was also observed in these
cells after treatment with EGCG. Interestingly, EGCG significantly suppressed cancer cell-invasive ability by decreasing the number of
invasive foci (Po0.0001) as well as invasion depth (Po0.005) in three-dimensional collagen invasion model. Although further
investigation is required to assess the extent of contribution of RECK on MMPs to the suppression of invasive behaviour, these results
support the conclusion that EGCG plays a key role in suppressing cell invasion through multiple mechanisms, possibly by
demethylation effect on MMP inhibitors such as RECK.
British Journal of Cancer (2008) 99, 647–654. doi:10.1038/sj.bjc.6604521 www.bjcancer.com
Published online 29 July 2008
& 2008 Cancer Research UK
Keywords: green tea polyphenol; EGCG; RECK hypermethylation; oral cancer invasion
                                           
Cancer development is a multistage process requiring progressive
genetic and epigenetic changes in neoplastic and responding
stromal cells. During the process of malignant progression,
migration of cells into the underlying extracellular matrices is a
fundamental feature of tumour invasion. The reversion-inducing
cysteine-rich protein with Kazal motifs (RECK), a novel matrix
metalloproteinases (MMPs) inhibitor, was originally isolated as a
transformation suppressor gene against activated ras oncogenes
(Takahashi et al, 1998; Oh et al, 2001; Sasahara et al, 2002; Noda
et al, 2003; Simizu et al, 2005; Chang et al, 2006). Previous studies
have revealed that RECK is able to inhibit tumour angiogenesis,
invasion, and metastasis. Its downregulation has been shown
in several types of human cancers. Recently, the decrease in
RECK expression is reported to correlate with hypermethylation
of the promoter region (Furumoto et al, 2000; Song et al, 2006;
Chang et al, 2007; Cho et al, 2007). In human cancers, aberrant
methylation of tumour suppressor genes is of comparable
significance to classic genetic mutations (Lund and van Lohuizen,
2004; Ha and Califano, 2006; Stresemann et al, 2006; Shaw, 2006).
The study of the patterns of gene silencing because of hyper-
methylation would therefore help to understand and predict
cancer cell behaviour and responsiveness to various treatments of
cancers (Hellebrekers et al, 2007; Shaw et al, 2007).
Tea is the most widely consumed beverage worldwide. Tea
components, especially green and black tea constituents, have been
reported to prevent carcinogenesis in vitro and in vivo (Jung and
Ellis, 2000; Benelli et al, 2002; Yang et al, 2002; Chung et al, 2003;
Fang et al, 2003; Fassina et al, 2004; Ju et al, 2005; Khan et al,
2006). Epigallocatechin-3-gallate (EGCG), the major polyphenol in
green tea, is believed to be a key active ingredient. Previous studies
have shown that EGCG is methylated by catechol-O-methyl-
transferase and inhibits DNA methyltransferase (DNMT). The
inhibition of DNMT would block the hypermethylation of
the newly synthesised DNA strand, resulting in the reversal of
the hypermethylation and the re-expression of the silenced genes
(Fang et al, 2003; Lund and van Lohuizen, 2004; Ha and Califano,
2006; Stresemann et al, 2006; Shaw, 2006; Hellebrekers et al,
2007; Shaw et al, 2007). Other DNMT inhibitors such as 5-aza-
20-deoxycytidine (5-aza-dC) and zebularine also have similar
inhibitory effect. Although there is a high potential for developing
this group of inhibitors for cancer therapy, side effects and toxicity
are serious concerns. The chemoprevention of cancer by tea
components as natural inhibitors of DNMT is therefore such a
promising approach with less side effects and toxicity (Chung et al,
2003; Lambert and Yang, 2003; Szyf et al, 2004; Ju et al, 2005;
Wilson et al, 2007).
In the present study, we determined the effects of EGCG
treatment on the methylation status and expression level of the
RECK gene in human oral squamous cell carcinoma cell lines. The
inhibition of oral carcinoma invasion by EGCG was also examined
by a three-dimensional collagen invasion model.
MATERIALS AND METHODS
Cell lines and cell cultures
Four human oral squamous cell carcinoma cell lines HSC3, HSC4,
SCC9, SCC25 and human cervical cancer cell line HeLa were
examined. These cell lines were obtained from Cell Resource
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sCenter for Biomedical Research (Tohoku University, Sendai City,
Japan). All cell lines were maintained in RPMI-1640 (Sigma-
Aldrich Company, St. Louis, MO, USA) supplemented with 10%
fetal bovine serum (FBS) (Life Technologies Inc., Gaithersburg,
MD, USA) and 50000U penicillin, 50mg streptomycin at 371Ci na
5% CO2 humidified atmosphere. The cancer cell lines were also
cultured in medium with 50mM EGCG (Wako Pure Chemical
Industries, Ltd., Osaka, Japan) or 8.7mM 5-aza-dC (MP Biomedicals,
LLC, Eschwege City, Germany) for 6 days and harvested for further
analyses as previously described (Fang et al, 2003). To determine the
dose-dependent changes, SCC9 and HSC3 cell lines were treated
with 5, 10, 20, or 50mM of EGCG or 8.7mM of 5-aza-dC for 6 days.
EGCG or 5-aza-dC was added, in new culture medium, to the cells
on days 1, 3, and 5. For the time course study, the cells were treated
with 50mM of EGCG for 36, 72, or 144h.
Bisulphite modification and methylation-specific PCR
One microgram of the purified DNA was subjected to bisulphite
modification. Bisulphite modification was performed using
CpGenomet DNA Modification Kit (Chemicon International,
Temecula, CA, USA) according to the manufacturer’s instructions.
For MSP, the following primer sets were used: for methylated DNA,
MF_RECK (50-GTTAGTTTTTTTTTTTATTTTAGTGGTTCGA-30)
and MR_RECK (50-TCCAAAACCTCCCGAAAACGAAAACG-30),
and for unmethylated DNA, UF_RECK (50-GGTTAGTTTTTTTT
TTTATTTTAGTGGTTTGA-30) and UR_RECK (50-ATTTCCAAAA
CCTCCCAAAAACAAAAACA-30). Reactions were performed in
20ml volumes under the following conditions: 951C for 10min;
then 40 cycles of 951C for 30s, 561C for 30s, and 721C for 30 s; and
finally 7min at 721C. The PCR product lengths for methylated and
unmethylated RECK are 201 and 205bp. CpGenome Universal
Methylated DNA (Serologicals, Atlanta, Georgia, USA) and normal
human blood DNA was used as positive control for methylated and
unmethylated status. Water blank was used as a negative control.
Positive and negative controls worked appropriately in each round
of PCR. All assays were performed in triplicate.
Reverse transcription–PCR and quantitative real-time
PCR
Total RNA was isolated from 10
5 to 10
6 cultured cells using a Trizol
reagent kit (Invitrogen, Carlsbad, CA, USA). cDNA was synthe-
sised from 1mg of total RNA using MMLV Reverse Transcriptase
(Invitrogen) with random hexamers. RECK cDNA was amplified by
PCR using the sense primer 50-GCAGGGGAAGTTGGTTGTTA-30
and antisense primer 50-TGCCAGCAAAACAAGAACAG-30. Reac-
tions were performed in 20ml volumes under the following
conditions: 951C for 10min; then 35 cycles of 951C for 30s, 601C
for 30s, and 721C for 30s; and finally 7min at 721C. Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) was used as an
internal control to estimate the efficiency of the cDNA synthesis in
each cell line with forward primer: 50-AGCATCTACACCTGAGGA
CAAGAC-30; reverse primer: 50-TTTTGCTCTTAACCACGTTTAT
TGA-30. The integrated optical density of each band was quantified
by densitometry. The relative levels of RECK mRNA were
normalised against the GAPDH.
Quantitative real-time PCR assay was performed using SYBR
s
Premix Ex Taqt in Thermal Cycler Dice
s (Takara, Tokyo, Japan).
The cycling conditions were initial denaturation at 951C for 10s,
and 40 cycles at 951C for 5s, 601C for 30s according to the
SYBR
sPremix Ex Taq (Perfect Real Time) protocol. Second
derivative maximum method was used to calculate the Ct
(threshold cycle) value and standard curve method was used for
relative quantification analysis. The Ct value of RECK was
normalised by the Ct of GAPDH in the same sample. Each reaction
was run in triplicate.
Gelatin zymography
Cancer cell lines were seeded in bio-coat culture disks (Becton
Dickinson Labware, Bedford, MA, USA) for 6 days. Fresh medium
without FBS was replaced 24h before analysis. MMP-2 and MMP-9
enzymatic activity in cancer cell lines was determined by sodium
dodecyl sulphate (SDS) polyacrylamide gel electrophoresis
(PAGE) gelatin zymography as described in our previous study
(Kato et al, 2005). In brief, the gelatinolytic activity was measured
in the presence of both proforms and activated forms of the
MMP-2 and MMP-9. The cell extract was diluted in the ratio
of 1:1 with sample buffer (TEFCO, Tokyo, Japan) and left at
room temperature for 10min. The cell extracts were applied to
SDS–PAGE using a 10% gel containing 0.1% gelatin. After
electrophoresis the gel was rinsed with renaturing buffer (TEFCO)
for 30min, and the gel was incubated in developing buffer
(TEFCO) for 48h at 371C. After incubation the gel was stained
with 0.05% Coomassie brilliant blue R250 (Wako Pure
Chemical Industries, Osaka, Japan). The MMPs were detected as
transparent bands on the blue background of the Coomassie blue
stained slab gel.
Collagen gel invasion model
Collagen gels were used as matrices for cancer cell invasion and
prepared according to the method of Hase et al (2006) with a little
adjustment. Type I collagen (Nippon Meat Packers Inc., Osaka,
Japan) was mixed with medium and  10 PBS at a ratio of 1:1:8
and air-vacuumed for 30min before incubated in 5% CO2 and 371C
until gelling was completed. Cancer cells (3 10
5) from each cell
line were seeded on the collagen gels in medium with and without
EGCG or 5-aza-dC. The cancer cells were maintained at 5% CO2
atmosphere and 371C for 7 and 14 days. The collagen gel was
collected and fixed in 10% formalin, embedded in paraffin, stained
with haematoxylin and eosin and examined for cancer cell
invasion.
Assays for cell invasion and migration
Cell invasion and immigration assays were used to assess the
formation of invasive foci and the depth of cell invasion into
the collagen matrix previously described by Hotary et al (2000)
and Liebersbach and Sanderson (1994). Six days after the
addition of cells to gels, invasive foci were counted in randomly
selected fields at  200 magnification on phase-contrast
microscope. The depth of cell invasion was determined by
measuring the distance from the top of the gel to the
leading front of migrating cells. The leading front distance was
defined as the point at which two of the most distantly migrating
cancer cells were simultaneously in focus in one field under  200
magnification. Measurements were made using the calibrated
micrometer of a Nikon inverted microscope. Measurements were
taken in five fields within each well, and the mean distance was
determined.
To measure cell proliferation rates, 8 10
4 cells were placed into
each culture plate and cultured for 3, 5, 7 days in medium without
and with 50mM EGCG and 8.7mM 5-aza-dC. At each time point,
the cells were harvested by trypsinisation and counted using
a hemacytometer.
Cell migration ability was assessed by seeding 2–5 10
5 cells
atop collagen gels with surfaces partially covered by glass
coverslips (1 2cm; Matsunami Glass Ind, Ltd., Osaka, Japan).
When the cells reach confluence, the glass fragments were
removed, leaving a cell-free area on the gel. At this time, medium
was added to all cultures in the absence or presence of EGCG and
5-aza-dC. The distances migrated across the gels were observed
24h later using an inverted microscope.
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Differences between treatment and control groups were assessed
by analysis of variance with post hoc test (Dunnett’s test).
Statistical analyses on the invasive foci and depth of invasion of
the cancer cell lines were performed using the Student’s t-test. The
results were considered statistically significant at Po0.05.
RESULTS
Methylation status and expression of the RECK gene in
OSCC cell lines
A hypermethylated RECK promoter was observed in all four OSCC
cell lines (100%) by MSP. SCC9 and SCC25 cell lines contained
both unmethylated and methylated promoters whereas HSC4 and
HSC3 cell lines had strongly methylated promoter and faintly
unmethylated promotor. Methylation of RECK gene was not
detected in HeLa cancer cell line whereas its unmethylation-
specific band appeared as a weak band (Figure 1A). The expression
levels of RECK mRNA in 4 human oral cancer cell lines and HeLa
were examined by RT–PCR. The results showed that the HSC3 and
HSC4 cell lines expressed very low RECK mRNA levels. SCC9 and
SCC25 cells had downregulated expression whereas HeLa pro-
duced a normal amount of RECK mRNA (Figure 1A).
Reversal of hypermethylation status and enhanced
expression of RECK gene in OSCC cell lines by EGCG
To evaluate whether methylation status of RECK promoter is
associated with transcriptional downregulation of RECK gene in
the OSCC cell lines, demethylation treatment by 5-aza-dC and
EGCG were performed on the OSCC cell lines. In all cancer cell
lines, the RECK gene had hypermethylation status with the low
level of the respective mRNA expression. The appearance of
unmethylation-specific bands of RECK gene in all four cancer cell
lines became more intense after treatment with 50mM EGCG or
8.7mM 5-aza-dC for 6 days. Treatment of SCC9 and HSC3 with
EGCG and 5-aza-dC for 6 days also enhanced the transcription of
RECK mRNA whereas RECK mRNA level was not significantly
altered in HSC4 and SCC25 after treatment with EGCG (Figure 1B).
We examined the time-dependent and dose-dependent effects of
EGCG in SCC9 and HSC3 cell lines. After treating cells with 5, 10,
20, or 50mM of EGCG for 6 days, the methylation-specific bands of
this gene still existed but in a weak appearance. The unmethyla-
tion-specific bands of RECK gene, however, appeared to be
enhanced after treatment with 20 or 50mM of EGCG for 6 days.
Corresponding to the appearance of the unmethylation-specific
band was the increase of expression of RECK mRNA by
conventional RT–PCR. The unmethylation-specific bands and
mRNA expression were significantly stronger with 50mM of EGCG
in comparison with those treated with 20mM EGCG or lower
concentrations (Po0.01). The reversal of hypermethylation and
increase of expression of RECK by EGCG were almost similar to
that produced by the classical DNMT inhibitor, 5-aza-dC. After
treating the cells with 50mM of EGCG for 36, 72, and 144h, strong
unmethylation-specific bands of the RECK gene began to appear at
72h. The higher level of mRNA expression of RECK was also
observed at 72 and 144h (Po0.01) (Figure 2).
To confirm the effect of EGCG on RECK expression, real-time
quantitative PCR was performed to determine the mRNA
expression level of RECK gene in HSC3 and SCC9 cell lines after
treatment with different concentrations of EGCG. The results
showed that the relative amount of mRNA expression of RECK was
increased in a dose- and time-dependent manner with significant
effect at 20 and 50mM EGCG (Po0.01 and Po0.001) and at 72 and
144h (Po0.01 and Po0.001). This result was generally consistent
with those from general reverse transcription–PCR, however,
with a significant effect at lower concentration of EGCG (20mM)
(Figure 3).
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Figure 1 Methylation status and mRNA expression levels of the RECK gene. (A) Methylation analysis of the RECK promoter and mRNA expression in
OSCC and HeLa cell lines. M, Methylation-specific band; U, Unmethylation-specific band; Blood DNA, normal human blood DNA as positive control for
unmethylated status; UMD, Universal methylated DNA as positive control for methylated status; H20, Negative control. (B) Alterations of methylation
status and mRNA expression levels of the RECK gene in OSCC cell lines after treatment with 50mM EGCG or 8.7mM 5-aza-dC for 6 days. GAPDH was used
as an internal control.
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Gelatin zymography results showed that MMP-2 and MMP-9
expression and activity were suppressed in SCC9 and HSC3 cells
treated with EGCG and 5-aza-dC for 6 days (Figure 4). Culture with
EGCG or 5-aza-dC decreased total MMP-2 levels and down-
regulated the activation of proMMP-2. Although proMMP-9 was
detectable, active forms of MMP-9 were not readily observed in
this experiment. Treatment with 50mM EGCG did not cause
downregulation in MMP-9 activity but MMP-2 in HSC4 and SCC25
cancer cell line (data not shown).
Inhibition of cancer invasion in collagen matrices by EGCG
When cultured atop collagen gels, SCC9, SCC25, and HeLa cells
formed confluent monolayers that remained confined to the
surface of the underlying gel for the entire culture period
regardless of the presence of EGCG or 5-aza-dC. We also did not
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Figure 2 Dose-dependent and time course study. SCC9 and HSC3 cells were treated with 5, 10, 20, or 50mM EGCG or 8.7mM 5-aza-dC for 6 days. Cell
lines were treated for 32, 72, and 144h with 50mM of EGCG. The relative levels of RECK mRNA were normalised to the GAPDH. Band density was
determined with densitometry. The bars represent mean±s.d. (n¼3). *Po0.01when compared with control.
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Figure 3 Relative mRNA expression levels of RECK gene by quantitative real-time PCR in HSC3 and SCC9 cell lines. EGCG enhanced RECK mRNA
expression in a dose- and time-dependent manner. Expression levels were normalised to the human GAPDH control gene, an endogenous control. All
expression levels are shown relative to the untreated sample. The bars represent mean±s.d. (n¼3). *Po0.01; **Po0.001when compared with control.
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However, treatment with EGCG significantly inhibits cancer-
invasive ability in collagen model in HSC4 and HSC3 cancer cell
lines (Figure 5A–D). During 7 days treatment with EGCG, HSC3
and HSC4 cells proliferated at a lower rate compared with those of
control or 5-aza-dC treated cells. Although treatment with 50mM
EGCG caused some damaged cells with vesicles, signs of toxicity
were not apparent at lower doses.
Our results indicated that treatment with 50mM EGCG
significantly inhibited cancer invasion in a three-dimensional
collagen model. Furthermore, EGCG or 5-aza-dC significantly
blocked cancer invasion in HSC3 cells by decreasing the mean
number of invasive foci/field (Po0.0001 and Po0.00001, respec-
tively). Results are shown as the mean number of invasive foci
±1 s.d. in five randomly selected fields in HSC3 cells treated with
5-aza-dC, EGCG and control (6±2 foci, 11.4±2.7 foci, and
26.4±3.8 foci, respectively). Interestingly, regarding cell migration
and depth of invasion, EGCG significantly inhibited cells to invade
deeply into the collagen gel compared with control (93±32.3 vs
191.2±33.7mm, Po0.005) as well as suppressed the cells migrating
across the gels surface (Figure 5B, D and 6A, B). Similar effects
were also observed in HSC4 cell line (Table 1).
In the presence of EGCG, HSC3 and HSC4 cells cultured atop
collagen gels for 6 days displayed widespread but shallow foci of
invasion. In contrast, control cells (EGCG-free medium) invaded
and generated large and deep pits extending well in the collagen
matrix. After 14 days, HSC3 cells cultured in the absence of EGCG
formed an aggressive invasion and proliferation (with stratified
5–6 cell layers) whereas invasion of HSC3 cells treated with
EGCG was markedly inhibited and only generated pits underlying
collagen gels (Figure 5C and D).
DISCUSSION
In the present study, we report that EGCG, a major component of
green tea, may enhance RECK expression by reversal of
hypermethylation of RECK promoter and inhibit MMP activities
as well as cancer cell invasion in OSCC cell lines. Recent studies
have also shown that RECK methylation is associated with increase
of metastasis and invasion in human cancers (Chang et al, 2006,
2007; Cho et al, 2007).
Our findings implied that the hypermethylation of RECK is
associated with a low level of mRNA expression in oral squamous
cell carcinoma cell lines. Of these, SCC9 and SCC25 cell lines were
partially methylated whereas HSC4 or HSC3 cells were almost
completely methylated. The results showed that treatment of oral
cancer cells with EGCG partially reversed the hypermethylation
status of the RECK gene and significantly enhanced the expression
level of RECK mRNA. EGCG has been reported to reverse
hypermethylation and reactivate several tumour suppressor genes
in human oesophageal squamous cell carcinoma cell lines at doses
from 20mM (Fang et al, 2003) by nested two-stage MSP. However,
present oral cancer cell lines appear to be less susceptible to a
demethylation effect by EGCG. Additional work is needed to
determine whether different genes respond similarly or differently
to the EGCG treatment in different cell lines under various
treatment conditions.
EGCG 5-aza-dC Control EGCG Control
Pro-MMP2 (72 kDa)
Active-MMP2 (62 kDa)
SCC9 HSC3
Pro-MMP9 (92 kDa)
5-aza-dC 
Figure 4 Gelatin zymography analysis. Clear zones of proform and active MMP-2 (72 and 62kDa) and relatively weaker MMP-9 bands (92kDa proform
and 82kDa active form) that attenuated following the 50mM EGCG or 5-aza-dC 8.7mM treatment for 6 days in SCC9 and HSC3 cells.
Control 50 M EGCG
Figure 5 Collagen gel invasion model. Treatment of EGCG for 6 days
inhibits cancer invasion in collagen model in HSC3 cells. (A) The collagen
gel was collected and fixed in 10% formalin, embedded in paraffin, stained
with haematoxylin and eosin and examined for cancer cell invasion.
Treatment with EGCG significantly inhibits invasion in collagen model for 6
days (Arrow is showing an invasive foci). (B) Cell migration ability was
suppressed in the presence of EGCG for 6 days. Cells atop collagen gels
with surfaces were partially covered by glass coverslips (1 2cm). When
the cells reach confluence, the glass fragments were removed, leaving a
cell-free area on the gel. The distances migrated across the gels were
observed 24h later using inverted microscope. (C) Inhibition of cell
invasion by EGCG in HSC3 cells for 14 days. (D) The ability of cancer cells
to migrate from the edge towards centre of the uncovered gel in HSC3
cells cultured with EGCG were decreased as compared to control on day
14 (after 24h of removing the cover slips) ( 100 magnification). The
arrows show the margin of the uncovered area on the gel.
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indirectly, in particular MMP-2 at relatively low doses (10–20mM).
EGCG has been reported to inhibit activating protein-1 (AP-1) that
regulates MMP expression. In another way, EGCG could also
inhibit the proMMP-2 protein secretion by perturbing the
intracellular vesicular trafficking (Oh et al, 2004; Khan et al,
2006). However, our data demonstrate that OSCC cell lines-derived
MMP-2 and MMP-9 were inhibited at 50mM of EGCG treatment.
Previous studies showed that restored expression of RECK in
malignant cells resulted in suppression of invasive activity with
concomitant decrease in the secretion of MMPs (Takahashi et al,
1998; Okabe et al, 1999; Liu et al, 2003; Noda et al, 2003). Treatment
with EGCG, HSC3 and HSC4 cells cultured on top of collagen gels
produced widespread but shallow foci of invasion whereas control
cells (EGCG-free medium) invaded and generated large and deep
pits extending well in the collagen matrix. This could be because of
the ability to regulate MMPs by RECK restored expression. Earlier
study has shown that stimulated RECK expression significantly
caused downregulation of MMP-2 and MMP-9 activities (Takahashi
et al, 1998; Liu et al, 2003; Oh et al, 2004). In experimental systems,
cellular invasion is reduced by the presence of endogenous tissue
inhibitors of MMPs (TIMPs) and RECK. Recently, TIMP-2 has been
reported to enhance expression of RECK through Rap1 signalling
resulting in an indirect, time-dependent inhibition of cell migration
(Oh et al, 2004). Our findings suggest that EGCG and 5-aza-dC may
act simultaneously through different target proteins such as TIMPs
and RECK to suppress invasion. Further study is needed to define
the extent of contribution of RECK on MMPs to the suppression of
cell-invasive behaviours.
The results support the conclusion that EGCG plays a crucial
role in inhibiting cell invasion of a collagen model. EGCG
significantly suppressed cancer-invasive ability in oral cancer
cell lines by decreasing the number of invasive foci and depth
of invasion as strong as classical DNMT inhibitor, 5-aza-dC.
Oral administration of green tea has been reported to inhibit
tumour genesis in different organs and multiple mechanisms may
be involved (Jung and Ellis, 2000; Khan et al, 2006; Chiang et al,
2006; Okabe et al, 1999). Importantly, these effects of EGCG have
been shown to be selective for cancer cells, as normal cells were not
affected by this treatment (Khan et al, 2006).
The present study indicated that the effective dose of EGCG in
inhibiting cancer invasion and migration is at 50mM.A ta
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Figure 6 Invasive foci formation and invasion depth of cancer cells were inhibited by EGCG. (A) On top of collagen gels ( 200 magnification) EGCG or
5-aza-dC significantly blocked cancer invasion in HSC3 cells by decreasing the mean number of invasive foci/field by t-test. Results are shown as the mean
number of invasive foci ±1 s.d. in five randomly selected fields (6 days). (B) Focal plane located 200mm below the top of collagen ( 100 magnification).
6 days after addition of HSC3 cells to gels, the depths of cell invasion of cells that had invaded the gel were significantly blocked in cells treated with EGCG.
Similar results were observed with HSC4 cell line (not shown).
Table 1 Mean number of invasive foci per field and depth of invasion in HSC3 and HSC4 cancer cell lines after treatment with 50mM EGCG or 8.7mM
5-aza-dC for 6 days
Number of invasive foci per field mean±s.d. Depth of invasion mean±s.d. (lm)
Cell line Control 50lM EGCG 8.7lM 5-aza-dC Control 50lM EGCG 8.7lM 5-aza-dC
HSC3 26.4±3.8 11.4±2.7
a 6.0±2.0
b 191.0±33.7 93.0±32.3
c 182.4±13.2
HSC4 17.6±2.9 10.2±0.8
d 10.6±3.6
c 234.6±27.9 180.4±16.1
a 206.4±25.9
aPo0.00001;
bPo0.0001;
cPo0.001;
dPo0.005 when compared with control by the Student’s t-test.
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affect cancer invasion or migration of the cells. It is achievable
in the oral cavity (in saliva) after drinking green tea and perhaps
in the stomach, esophagus and the intestines where there is
direct contact between EGCG and the epithelial cells (Fang et al,
2003). This effective concentration is variable in different organs
and the DNMT inhibition would depend on the systemic
bioactivities and the bioavailability of EGCG in a particular organ
site. Inhibition of DMNT is expected to prevent hypermethylation;
however, severe inhibition of DNMT activity may cause DNA
hypomethylation, genomic instability and other disorders (Szyf
et al, 2004; Wilson et al, 2007). The effects of EGCG in vitro have
been obtained with relatively high concentrations than observed in
the plasma or tissues of animals or in human plasma after the
administration of green tea or EGCG (Masuda et al, 2001; Khan
et al, 2006). Therefore, it is not clear whether the activities
observed with high EGCG concentrations in cell lines can be
observed in vivo. More comprehensive studies in animal models
and humans are needed to determine the optimal doses and side
effects of EGCG.
In conclusion, our findings raise the possibility that EGCG could
inhibits cancer cell invasion through reversal of hypermethylation
status of RECK and downregulation of MMP-2 and MMP-9. Our
data together with earlier studies indicate that EGCG as a natural
demethylating agent could be a promising therapeutic strategy
for the development of combination chemopreventive/chemo-
therapeutic approaches in oral cancer treatment. Additional
investigations are required to fully elucidate the molecular
mechanisms by which green tea constituents, and EGCG in
particular, inhibit tumour invasion and metastasis.
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